Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | A Phase I/II study evaluating quizartinib plus decitabine and venetoclax in FLT3-mutated AML

Musa Yilmaz • 31 May 2022

EHA 2022

Acute Myeloid Leukemia Leukemia Decitabine Quizartinib Venetoclax

Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I/II trial investigating the efficacy of the combination of quizartinib plus decitabine and venetoclax in patients with FLT3-mutated acute myeloid leukemia (AML). Dr Yilmaz first provides some background information on the patients enrolled in this trial, and then discusses the response rates and toxicities observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Pfizer: Research Funding; Pint Pharma: Honoraria; Daiichi Sankyo: Research Funding

Sorafenib as maintenance therapy for patients with transplant-ineligible or post-alloSCT AML

Musa Yilmaz • 10 Dec 2023

Second-generation FLT3 inhibitors in the treatment of FLT3-ITD AML

Musa Yilmaz • 10 Dec 2023

Quizartinib, venetoclax, and decitabine in patients with FLT3-ITD AML: a Phase I/II trial

Musa Yilmaz • 10 Dec 2023

Phase Ib/II trial of quizartinib, decitabine and venetoclax in FLT3-ITD-mutated AML

Musa Yilmaz • 7 Dec 2020

Related Videos

Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens

Christina Peters • 15 Apr 2024

Promising novel agents in AML: menin inhibitors

Mark Levis • 16 Apr 2024

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024